20 May 2003
The impact of obesity and liver steatosis on the rate of liver fibrosis among patients with chronic hepatitis C
W. Kryczka, M. Chrapek, K. Paluch, D. Zarębska-Michaluk, A. UrbaniakMed Sci Monit 2003; 9(2): 9-0 :: ID: 15235
Abstract
Background:To study the potential predictive role of obesity and liver steatosis (LS)on the rate of liver fibrosis (RLF)among patients with chronic hepatitis C (CHC).Material/Methods:354 consecutive,biopsy proven (assessed according to Ishak ’s criteria)patients (mean age at biopsy: 42 ±14 years;F/M:178/176)with untreated CHC and known probable duration of HCV infection were seen.Subject with other forms of liver disease as well as heavy drinkers were excluded from analysis.The RLF was defined as the ratio between fibrosis stage (scored 0 –6 units with 6 representing cirrhosis)and the duration of infection (in years). Based on published data,a patient with RLF>/=0,3 (cirrhosis up to 20 years after HCV infection)was considered as rapid progressor. The obesity was defined as body mass index >30 kg/m 2 .In our analysis,the LS was graded as 0,1,2 respectively to less than 1% (or absence),1 –10%and more than 10%hepatocytes involved. Results: Overall, 15% (54/354)patients were rapid progressors. 13%(46/354)patients were obese and the grade 0,1 and 2 of LS was observed in 58% (201/354), 34%(121/354) and 9% (32/354)of patients, respectively.The rapid progressors were significantly more frequently noted among obese than among non-obese patients (30%vs.13%;p=0,004)as well as among patients with increasing LS (12%,17%and 28%rapid progressors,respectively among patients with grade 0,1 and 2 of LS; p=0.04).In logistic regression analysis,after adjusting for age at biopsy and sex,only obesity (adjusted OR=2,2; 95%CI [1.1 –4.7 ];p=0.03)and not LS (p=0.21)was an independent predictor of rapid progression to cirrhosis.Conclusions:Our study confirmed recently published findings indicating that obesity maybe considered as a predictor of rapid disease progression in CHC patients.It suggests that weight reduction may play a significant role in hepatitis C management and constitute an alternative,especially among non-responders or patients with contraindications to interferon therapy
Editorial
01 April 2024 : Editorial
Editorial: Forty Years of Waiting for Prevention and Cure of HIV Infection – Ongoing Challenges and Hopes for Vaccine Development and Overcoming Antiretroviral Drug ResistanceDOI: 10.12659/MSM.944600
Med Sci Monit 2024; 30:e944600
In Press
05 Mar 2024 : Clinical Research
Role of Critical Shoulder Angle in Degenerative Type Rotator Cuff Tears: A Turkish Cohort StudyMed Sci Monit In Press; DOI: 10.12659/MSM.943703
06 Mar 2024 : Clinical Research
Comparison of Outcomes between Single-Level and Double-Level Corpectomy in Thoracolumbar Reconstruction: A ...Med Sci Monit In Press; DOI: 10.12659/MSM.943797
21 Mar 2024 : Meta-Analysis
Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, a...Med Sci Monit In Press; DOI: 10.12659/MSM.943863
10 Apr 2024 : Clinical Research
Predicting Acute Cardiovascular Complications in COVID-19: Insights from a Specialized Cardiac Referral Dep...Med Sci Monit In Press; DOI: 10.12659/MSM.942612
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952